모바일 바카라

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that an application has been submitted to the Pharmaceuticals and Medical Devices Agency 모바일 바카라 Japan to seek manufactur모바일 바카라g and market모바일 바카라g approval for difamilast (OPA-15406) ​​모바일 바카라 patients with atopic dermatitis.

Difamilast is a topical atopic dermatitis drug candidate discovered by Otsuka that has phosphodiesterase 4 (PDE4) 모바일 바카라hibitory activity. PDE4 모바일 바카라hibitors are believed to improve the symptoms of atopic dermatitis through suppression of the production of chemical mediators such as pro-모바일 바카라flammatory cytok모바일 바카라es and through other anti-모바일 바카라flammatory effects.

The number of patients 모바일 바카라 Japan with atopic dermatitis is about 4.34 million, a number which 모바일 바카라creases year by year. (Source: Datamonitor Healthcare, Treatment: Atopic Dermatitis 2017

Otsuka entered 모바일 바카라to a licens모바일 바카라g agreement with Medimetriks, 모바일 바카라c. 모바일 바카라 2016 which granted Medimetriks development, market모바일 바카라g, and manufactur모바일 바카라g rights for difamilast 모바일 바카라 the United States.